KB Home (NYSE:KBH – Free Report) – Stock analysts at Seaport Res Ptn dropped their FY2025 earnings per share estimates for KB Home in a research report issued to clients and investors on Sunday, November 3rd. Seaport Res Ptn analyst K. Zener now expects that the construction company will post earnings per share of $8.41 for the year, down from their prior forecast of $8.78. The consensus estimate for KB Home’s current full-year earnings is $8.44 per share.
KB Home (NYSE:KBH – Get Free Report) last issued its quarterly earnings results on Tuesday, September 24th. The construction company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.06 by ($0.02). The business had revenue of $1.75 billion for the quarter, compared to analyst estimates of $1.73 billion. KB Home had a return on equity of 15.69% and a net margin of 9.31%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.80 EPS.
KB Home Trading Up 2.2 %
Shares of KB Home stock opened at $79.70 on Tuesday. The stock’s fifty day simple moving average is $82.32 and its 200 day simple moving average is $76.27. The company has a market capitalization of $5.84 billion, a PE ratio of 10.22, a PEG ratio of 0.66 and a beta of 1.81. KB Home has a 12 month low of $50.08 and a 12 month high of $89.70.
KB Home Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Thursday, November 14th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, November 14th. This represents a $1.00 annualized dividend and a dividend yield of 1.25%. KB Home’s dividend payout ratio is 12.82%.
Insider Activity at KB Home
In other news, CFO Jeff Kaminski sold 27,500 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $79.40, for a total value of $2,183,500.00. Following the completion of the transaction, the chief financial officer now owns 34,473 shares of the company’s stock, valued at approximately $2,737,156.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.52% of the stock is currently owned by insiders.
Hedge Funds Weigh In On KB Home
Several large investors have recently bought and sold shares of the company. Hancock Whitney Corp increased its stake in shares of KB Home by 311.0% in the first quarter. Hancock Whitney Corp now owns 16,219 shares of the construction company’s stock valued at $1,150,000 after buying an additional 12,273 shares during the period. Virtu Financial LLC bought a new position in shares of KB Home during the first quarter valued at $1,078,000. Entropy Technologies LP acquired a new position in shares of KB Home during the first quarter worth $640,000. SG Americas Securities LLC grew its stake in shares of KB Home by 1,333.9% in the first quarter. SG Americas Securities LLC now owns 42,342 shares of the construction company’s stock worth $3,001,000 after purchasing an additional 39,389 shares during the last quarter. Finally, Tidal Investments LLC bought a new position in KB Home during the 1st quarter worth $1,177,000. 96.09% of the stock is currently owned by institutional investors.
KB Home Company Profile
KB Home operates as a homebuilding company in the United States. It operates through four segments: West Coast, Southwest, Central, and Southeast. It builds and sells various homes, including attached and detached single-family residential homes, townhomes, and condominiums primarily for first-time, first move-up, second move-up, and active adult homebuyers.
Recommended Stories
- Five stocks we like better than KB Home
- What Investors Need to Know About Upcoming IPOs
- Intel: Is Now the Time to Be Brave?Â
- What Investors Need to Know to Beat the Market
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for KB Home Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KB Home and related companies with MarketBeat.com's FREE daily email newsletter.